Bladder cancer is the fourth most common cancer among males in the US and due to its prevalence among the over 65s, diagnoses are set to increase in ageing populations worldwide. Reports in the Bladder Cancer section cover a variety of areas, such as the latest R&D and clinical trials taking place in universities, hospitals and other research centres around the world. Explore epidemiology, unmet needs, drug development (cytotoxic, immunotherapy agents, etc.), supply & demand, business development
strategies, licensing and partnership opportunities, and the activities of key industry players such as Bristol-Myers Squibb, Spectrum Pharmaceuticals, Bioniche Life Sciences, Endo Pharmaceuticals, Eli Lilly and Sanofi-Aventis.